Compare Neurocrine Biosciences Inc (NBIX) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Plby Group Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.85 (market cap $15.77B), while Plby Group Inc trades at $1.16 (market cap $138.38M). The key difference: Neurocrine Biosciences Inc is far larger — about 114× Plby Group Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PLBY | |
|---|---|---|
Market Cap | $15.77B | $138.38M |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $2.71 |
52-Week Low | $123.10 | $1.11 |
Enterprise Value | $15.78B | $283.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
PLBY trades at $1.18, up 0.85% with a bearish technical signal despite positive cash flow trends. The company shows improving fundamentals with revenue stabilizing around $120M and net losses narrowing significantly from -$278M in 2022 to -$13M in 2025. Recent Q2 2026 earnings beat expectations with a return to operating profitability, while analyst consensus remains strongly bullish with 75% buy ratings.
The outlook suggests cautious optimism as PLBY demonstrates operational turnaround with five consecutive quarters of positive EBITDA. Key risks include high debt levels and negative shareholder equity, but recent share repurchases and Russell index inclusion provide support. The stock faces resistance near current levels with technical indicators signaling caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
